Search Within

Bone Marrow Transplant

Formats
  1. Meeting Abstract (1531)
  2. Journal Article (1197)
  3. Review (75)
  4. Research Letter (48)
  5. Book Section (34)
  6. Guidelines (26)
  7. Editorial (24)
  8. Correspondence (18)
  9. Conference Paper (14)
  10. Book Whole (1)
  11. Miscellaneous (1)
Groups
  1. Center for Hematologic Malignancies (2969)
  2. Department of Medicine (2969)
  3. Hematologic Malignancies, Division of (2846)
  4. Survivorship Research (1387)
  5. GSK Faculty (931)
  6. CTCR Scholars (872)

More Groups

People
  1. Sergio Giralt (1067)
  2. Miguel-Angel Perales (942)
  3. Sean Devlin (469)
  4. Ann Jakubowski (458)
  5. Gunjan Shah (446)
  6. Heather Landau (435)

More People

Years
  1. 2025 (66)
  2. 2024 (212)
  3. 2023 (263)
  4. 2022 (201)
  5. 2021 (177)
  6. 2020 (208)

More Years

Publications
  1. Blood (887)
  2. Biology of Blood and Marrow Transplantation (516)
  3. Bone Marrow Transplantation (175)
  4. Journal of Clinical Oncology (127)
  5. Transplantation and Cellular Therapy (113)
  6. Blood Advances (94)

More Publications

Publishers
  1. American Society of Hematology (988)
  2. Elsevier Inc. (766)
  3. Nature Publishing Group (261)
  4. American Society of Clinical Oncology (130)
  5. Wiley Blackwell (66)
  6. Taylor & Francis Group (65)

More Publishers

Results (2969)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • The Composite Health Risk Assessment Model (CHARM) predicts risks of toxicities, functional and cognitive decline among survivors of allogeneic hematopoietic cell transplantation (allo-HCT): A prospective BMT-CTN study 1704
    Meeting Abstract

    Sorror, M.; Saber, W.; Logan, B. R.; Geller, N.; Bellach, A.; Kou, J.; Wood, W. A.; McCarty, J. M.; Knight, T. G.; Runaas, L.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Immune-MRD status informs tumor-MRD outcome prognostication in multiple myeloma patients on lenalidomide maintenance
    Meeting Abstract

    Firestone, R. S.; Simhal, A. K.; McAvoy, D.; Jurgens, E. M.; Garcés, J. J.; Nemirovsky, D.; Derkach, A.; Maclachlan, K. H.; Hultcrantz, M.; Mailankody, S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • A high-fiber dietary intervention (NUTRIVENTION) in precursor plasma cell disorders improves biomarkers of disease and may delay progression to myeloma
    Meeting Abstract

    Shah, U. A.; Cogrossi, L. L.; Derkach, A.; Castro, F.; Fei, T.; DeWolf, S.; Garces, J. J.; Policastro, A.; Grioni, M.; Sisti, S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Cross-talk between leukemic blasts and T cells drives targetable T cell dysfunction in the AML tumor microenvironment
    Meeting Abstract

    DeWolf, S.; Ceglia, N.; Zatzman, M.; Gipson, B.; Elhanati, Y.; Katsamakis, Z.; Lees, H.; Weis, K.; Yepes, G.; Oliveira, B.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Pembrolizumab maintenance instead of autologous hematopoietic cell transplantation for patients with relapsed or refractory Hodgkin lymphoma in complete response after pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin
    Meeting Abstract

    Moskowitz, A.; Shah, G. L.; Ganesan, N.; Chang, T.; Drill, E.; Davey, T.; Hancock, H.; Munayirji, B.; Douglas, M.; Santarosa, A. M.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Long-term follow up of a prospective pilot study of an α/β T-lymphocyte depleted graft conditioned with a reduced intensity regimen in patients with hematologic malignancies
    Meeting Abstract

    Hughes, C. F. M.; Lin, R. J.; Devlin, S. M.; Shaffer, B. C.; Jakubowski, A. A.; Talla, V.; Saldia, A.; Gyurkocza, B.; Papadopoulos, E. B.; Giralt, S. A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Increased fiber intake results in better overall survival and lower GI-aGVHD in allo-HCT recipients and pre-clinical GVHD models
    Meeting Abstract

    Paredes, J.; Fei, T.; Dai, A.; Ramos, R.; Adintori, P.; Kousa, A.; Nguyen, C. L.; Victor, K.; Ghale, R.; Pohl, C.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • A CD33-deleted allograft (trem-cel) enables post-hematopoietic cell transplant (HCT) maintenance dosing of gemtuzumab ozogamicin (GO) with therapeutic levels of drug exposure and low hematologic and hepatic toxicity in patients with high-risk acute myeloid leukemia (AML)
    Meeting Abstract

    DiPersio, J. F.; Koehne, G.; Shah, N. N.; Bernard, L.; Suh, H. C.; Koura, D.; Perales, M. A.; Tamari, R.; Mushtaq, M. U.; Maakaron, J. E.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Development of the ASH Research Collaborative Multiple Myeloma Program: A multicenter, real-world evidence generation network
    Meeting Abstract

    Kumar, S.; Wood, W. A.; Anderson, K. C.; Semmel, E. A.; James, S.; Neuberg, D. S.; Hewitt, K.; Schroeder, M. A.; Chung, D. J.; Rosenberg, A. S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • 24-hour urine testing does not add value to multiple myeloma response assessments: A secondary analysis of BMT CTN 0702
    Meeting Abstract

    Banerjee, R.; Fritz, A. R.; Akhtar, O. S.; Freeman, C. L.; Cowan, A. J.; Shah, N.; Landau, H. J.; Kumar, S.; Vogl, D. T.; Efebera, Y. A.; more...
    Blood (2024)

    Fulltext@MSK | Save